-
Hinyokika Kiyo. Acta Urologica Japonica Feb 1983The prophylactic and chemotherapeutic efficacy of PMPC against infections after TUR-P has been investigated. Bacteriological evaluation: PMPC , 200-300 mg/day for 2-12...
The prophylactic and chemotherapeutic efficacy of PMPC against infections after TUR-P has been investigated. Bacteriological evaluation: PMPC , 200-300 mg/day for 2-12 weeks, was administered to 49 patients, who had over 10(3)CFU/ml of microorganisms after CET or CEC treatment for 3-7 days. The eradication rate of microorganisms was 40.8% after 2 weeks, 52.2% after 4 weeks, 64.1% after 6 weeks, 65.0% after 8 weeks and 70.6% after 12 weeks. Effectiveness on pyuria : The improvement rate of pyuria against 59 patients who had over 10(5)/hpf of pyuria , was 15.3% after 2 weeks, 16.4% after 4 weeks, 25.4% after 6 weeks, 58.5% after 8 weeks, 72.7% after 10 weeks and 75.0% after 12 weeks. Overall clinical efficacy on PMPC was examined in 26 patients. The results of efficacy were 27.3% after 2 weeks, 48.0% after 4 weeks, 50.0% after 6 weeks, 69.2% after 8 weeks, 75.0% after 10 weeks and 77.0% after 12 weeks. The clinical response was evaluated according to a criterion for clinical evaluation of antimicrobial agent on chronic complicated UTI proposed by UTI committee in Japan. No severe adverse effect including allergic reaction was found. Following administration of PMPC , three patients experienced adverse gastric reactions, and drug administration was discontinued at week 6 or 8. PMPC was effective as a prophylactic chemotherapeutic drug against infections after TUR-P and prostatectomy.
Topics: Age Factors; Amdinocillin Pivoxil; Drug Evaluation; Humans; Male; Penicillanic Acid; Postoperative Care; Postoperative Complications; Premedication; Prostatectomy; Prostatic Hyperplasia; Pyuria; Urinary Tract Infections
PubMed: 6203380
DOI: No ID Found -
Antimicrobial Agents and Chemotherapy May 1981For serum-resistant clinical isolates of Escherichia coli were grown in the presence of various subinhibitory concentrations of mecillinam or pivmecillinam and then...
For serum-resistant clinical isolates of Escherichia coli were grown in the presence of various subinhibitory concentrations of mecillinam or pivmecillinam and then exposed to the bactericidal action of human serum. All strains became more serum susceptible as a result of pregrowth in medium containing mecillinam, but the concentration of antibiotic needed to produce the effect varied according to the strain being used. Production of ovoid or round cells was a prerequisite for sensitization to serum. Growth in the presence of mecillinam did not alter the response to serum of a serum-susceptible E. coli strain.
Topics: Amdinocillin; Amdinocillin Pivoxil; Blood Bactericidal Activity; Escherichia coli; Humans; Infant, Newborn; Infant, Newborn, Diseases; Meningitis; Penicillanic Acid; Urinary Tract Infections
PubMed: 6271047
DOI: 10.1128/AAC.19.5.786 -
British Medical Journal Nov 1978
Topics: Adult; Aged; Amdinocillin; Amdinocillin Pivoxil; Carrier State; Convalescence; Humans; Middle Aged; Penicillanic Acid; Salmonella Infections
PubMed: 214204
DOI: 10.1136/bmj.2.6150.1502-b